Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
196
resultados
Última actualización
23/10/2026 [06:53:00]
Resultados 125 a 150 de 196
Resumen de: US20260268225A1
Techniques for determining insulin therapy are described. The techniques include obtaining patient characteristic information and one or more target therapy efficacy metrics representative of a desired clinical outcome for a current patient. The techniques may further include providing the patient characteristic information and the one or more target therapy efficacy metrics as an input to a machine-learning model, wherein the machine-learning model has been trained to determine an insulin delivery therapy that will cause the current patient to achieve the desired clinical outcome represented in the one or more target therapy efficacy metrics based on the current patient having the patient characteristic information. The techniques may further include determining the insulin delivery therapy based on an output of the machine-learning model. The techniques may further include outputting information indicative of the determined insulin delivery therapy.
Resumen de: EP4803002A1
0001 According to one embodiment, a wearable electronic device comprises a first sensor, at least one second sensor, a memory, a display, a communication circuit and at least one processor, wherein the memory can store instructions that, when executed by the at least one processor, cause the wearable electronic device to: identify, on the basis of a first sensing value identified through the at least one second sensor, a first time point so as to measure first blood glucose data of a user wearing the wearable electronic device; use an external device at the first time point so as to display, through the display, first guide information for allowing the blood glucose of the user to be measured; measure, through the first sensor, a second sensing value indicating a first biometric signal of the user at the first time point; acquire, through the communication circuit, information indicating a first blood glucose value of the user measured at the first time point by the external device; and acquire, on the basis of the first blood glucose value and a second sensing value indicating the first biometric signal, calibration data for determining a blood glucose value of the user on the basis of sensing values indicating biometric signals of the user to be measured using the first sensor.
Resumen de: EP4802998A2
0001 This application discloses a continuous glucose concentration monitoring method based on a multi-working-electrode system, a continuous glucose concentration monitoring device based on a multi-working-electrode system, a computer program, a computer-readable medium and a method for preparing continuous glucose concentration monitoring device based on a multi-working-electrode system. The method includes: obtaining, by using a first working electrode, a first current value used for representing a glucose concentration of a host, and obtaining, by using a second working electrode, a second current value used for representing the glucose concentration of the host, where the first working electrode and the second working electrode are separately and independently disposed on a same substrate, and the first working electrode includes a first parameter, and the second working electrode includes a second parameter; and determining a target glucose concentration according to the first current value as well as the first parameter and/or the second parameter as well as the second current value, where the first parameter is determined based on the second parameter and the second current value. In this application, a measurement error caused by a single electrode is reduced by using the first working electrode and the second working electrode, to improve accuracy of glucose concentration monitoring, and reduce a monitoring result deviation caused by an electrode difference.
Resumen de: GB2704605A
A system comprising a device for collecting a breath sample from a user, a spectrophotometer for measuring volatile organic compounds (VOCs), and a processor, which is configured to analyse the measured VOCs using machine learning models and classifying the user based on combinations of the VOCs as healthy, prediabetic or having Type 1 or Type 2 diabetes. The data points may additionally comprise the result of an associated glucose level, a HbA1c test, or an oral glucose tolerance test, and potentially data on one or more of age, sex, weight, height, and body mass index. The VOCs may exclude saturated hydrocarbons, or may exclude all hydrocarbons.
Resumen de: US12727758B1
A modular diagnostic system is disclosed for acquiring Raman spectral data from tear film and analyzing biochemical signatures using Artificial Intelligence (AI). The system includes a Raman excitation source, a spectral acquisition module, and a processing engine configured to perform baseline correction, feature extraction, and AI-based classification. The system enables real-time, non-invasive diagnostics for dry eye disease, diabetes, metabolic disease, pharmacologic agents, and other conditions. The system supports longitudinal tracking and EMR integration. Real-time outputs support clinical diagnosis, treatment guidance, and longitudinal monitoring.
Resumen de: WO2020067628A1
The present invention relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Resumen de: WO2026182442A1
Disclosed is an electronic device. The electronic device comprises: at least one sensor; memory storing a machine learning model and instructions; and at least one processor. When the instructions are individually or collectively executed by the at least one processor, the electronic device: obtains a PPG signal of a user by using the at least one sensor; performs preprocessing on the PPG signal by using a filter; obtains a power spectrum by converting the preprocessed PPG signal into frequency over time; obtains an average spectrum power for each frequency by calculating an average value of the obtained power spectrum over time; and obtains information about diabetes of the user by inputting the obtained average spectrum power for each frequency to the machine learning model.
Resumen de: WO2026182236A1
The present disclosure provides, for example, a cell cryopreservation composition capable of protecting cells during cell freezing without substantially adding an organic solvent cell cryopreservation agent. A cell cryopreservation composition according to the present disclosure contains a sugar or a derivative thereof and/or a surfactant.
Resumen de: US20260260730A1
A method of administering insulin includes receiving scheduled glucose time intervals and obtaining glucose data of a patient that includes glucose measurements, glucose times, and insulin dosages previously administered by the patient. The method also includes applying a set of filters to identify which of the glucose measurements associated with at least one of the scheduled time intervals are usable and which of the glucose measurements associated with the at least one scheduled time interval are unusable. The method also includes aggregating the glucose measurements associated with the at least one scheduled time interval identified as usable to determine a representative aggregate glucose measurement and determining a next recommended insulin dosage for the patient based on the representative aggregate glucose measurement and the insulin dosages previously administered by the patient.
Resumen de: MX2026008374A
Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time- correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.
Resumen de: US20260257014A1
Disclosed herein are systems and methods incorporating an ambulatory infusion pump and a CGM. These systems that can include software and related methods to provide improved automated insulin delivery algorithms that enable the algorithms to safely continue delivering insulin for some time periods of missing or known inaccurate glucose values.
Resumen de: US20260258368A1
0000 Methods are provided for in vitro selection of metabolic selection of metabolically selectable mammalian cells that don't require exogenous glucose and glutamine in culture. Such cells may be glycogen-storing mammalian cells, including without limitation hepatocytes. Metabolic selection provides an approach to rapidly kill non-selectable cells by withholding specific nutrients from the culture medium.
Resumen de: EP4800372A2
0001 A continuous glucose monitoring system may utilize electrode current (Isig) signals, Electrochemical Impedance Spectroscopy (EIS), and Vcntr values to optimize sensor glucose (SG) calculation in such a way as to enable reduction of the need for blood glucose (BG) calibration requests from users.
Resumen de: EP4800695A2
0001 Techniques for performing application-layer security and communication over primary invitation channels are disclosed. In certain embodiments, analyte data is obtained from an analyte sensor electrically coupled to a sensor electronics module of an analyte sensor system. A secret key is established with a display device over one or more primary invitation channels. The analyte data is encrypted using the secret key. The encrypted analyte data is broadcast over the one or more primary invitation channels.
Resumen de: EP4800696A1
The present invention relates to a computer implemented training method for training a first artificial intelligence agent for glycemic control of a patient and also relates to a computer implemented method of determining an insulin dose value for a patient next to administer and for administration by an insulin administration device based on a treatment algorithm comprising a first artificial intelligence agent.
Resumen de: EP4799662A1
The invention discloses a method and system for postprandial insulin infusion based on identifiable feature of diabetic, acquiring a food image by an imaging mechanism, and analyzing the food image by the food image recognition model to obtain food data, retrieving a narrow insulin algorithm adapted to the patient's own identifiable features from the cluster of narrow insulin algorithms according to the identifiable features of the patient, for calculation of insulin infusion amount during meals, compared to the preset insulin algorithm, the narrow insulin algorithm is more applicable to the physiological characteristics and living habit of the patient, the calculated postprandial insulin infusion amount is more accurate, and is beneficial for the treatment of diabetic.
Resumen de: EP4800534A2
The subject matter disclosed herein provides methods for presenting glucose level data. Glucose data for a patient may be received. A current glucose level and a rate of change of the current glucose level may be determined based on the received glucose data. A first interface may be displayed on a screen of a device. The first interface may include a unitary icon. The unitary icon may display the current glucose level and a visualization of the rate of change. Related apparatus, systems, techniques, and articles are also described.
Resumen de: US12721549B1
0000 A wearable medical monitoring device comprises a microneedle array configured to extract interstitial or capillary fluid from a user, biosensors configured to detect biomarkers including glucose and complete blood count parameters such as white blood cells, red blood cells, hemoglobin, hematocrit, and platelet count, a microprocessor configured to generate biomarker data from biosensor signals, and a wireless communication module configured to transmit biomarker data to a user device for forwarding to a server. The server analyzes biomarker data using machine learning models including time-series forecasting, anomaly detection, classification, and ensemble models to detect health condition anomalies and generate alerts. The machine learning models are updated via federated learning using anonymized data. The server establishes personalized baseline values and dynamically adjusts alert thresholds based on user-specific factors and environmental context.
Resumen de: MA70860A1
The invention concerns a smart ring designed to monitor the user's vital parameters and predict the risk of developing acute coronary syndrome (ACS). This watch incorporates advanced signal processing techniques and sophisticated algorithms to analyze heart rate variability as well as total cholesterol, blood glucose and blood pressure levels associated with acute coronary events. The vital data is sent to a server via an NB-IoT communication module, and visualized using a web interface. An integrated artificial intelligence model continuously analyzes the processed data to identify patterns indicative of ACS. If a high risk of ACS is detected, the ring emits visual and audible alerts, prompting the user to seek immediate medical attention. In addition, a user interface offers the possibility of viewing data and forecasts in real time, enabling continuous, proactive monitoring. This invention enables early detection of ACS thanks to improved analysis of vital parameters and the use of artificial intelligence for continuous real-time monitoring, thus improving the safety of preventive medical measures and the well-being of the user.
Resumen de: CN122648353A
The invention discloses a serum-free medium for efficiently enriching tumor stem cells and application of the serum-free medium, and belongs to the technical field of cell biology. The serum-free culture medium comprises a basic culture medium, basic additive factors and functional additive components, wherein the functional additive component comprises the following components: 1 mu M to 1 mu M of dimethyl alpha-ketoglutarate, 10 nM to 10 mu M of butyl benzyl phthalate, 0.01 mu M to 1 mu M of endothelin-1, 0.01 mM to 1 mu M of uridine diphosphate glucose, and 1 nM to 100 nM of tetrabromobisphenol A. According to the invention, a functional additive component is added into the serum-free culture medium, so that a stable dryness maintenance condition is provided for tumor stem cells; meanwhile, due to the synergistic effect of the functional added components and other components, the enrichment efficiency of the tumor stem cells is remarkably improved, and the advantage of low cost is achieved; therefore, the method has a relatively good application prospect in efficient enrichment of tumor stem cells.
Resumen de: CN122643107A
The invention discloses a paper-based micro-fluidic intelligent wound monitoring bandage based on a laser-induced graphene electrode array and a preparation and signal processing method of the paper-based micro-fluidic intelligent wound monitoring bandage. The bandage comprises a calcium alginate/zinc oxide antibacterial substrate, a wax printing paper base lateral chromatography microfluidic channel layer, a CO2 laser direct writing LIG multifunctional electrode array, a colorimetric indication area, an NFC wireless communication module and a silver nanowire electric control drug release module. The LIG electrode is used for detecting uric acid, lactic acid, glucose and pH value respectively after enzyme immobilization and chemical modification; detecting bacterial protease and TNF-alpha by using a paper-based colorimetric disk; and the NFC radio frequency field is used for supplying energy to realize battery-free work. The built-in signal processing method comprises the steps of temperature compensation, cross interference elimination, multi-parameter fusion infection risk scoring and double-threshold closed-loop drug delivery decision making. The preparation process mainly comprises laser direct writing, silk-screen printing and ionic crosslinking, is low in material cost, is green and environment-friendly, and is suitable for household and clinical closed-loop monitoring and treatment of chronic wounds.
Resumen de: CN122658581A
The invention relates to the technical field of health management, in particular to a health management system which comprises a user terminal, a wearable monitoring terminal, a drinking water monitoring terminal, a meal information acquisition end, a nutrition auditing end, a meal supply end and a cloud management platform. The wearable monitoring terminal is used for collecting physiological monitoring data such as heart rate, blood pressure, blood sugar and exercise electrocardio of a user at regular time; the water drinking monitoring terminal is used for collecting the water drinking amount and the water drinking time of a user, and reminding when water drinking does not reach a stage target; the meal information collection end is used for collecting meal identification codes on meal packages so as to obtain food material types, calories, quantities, meal times and allergen information of meals. According to the invention, closed-loop management of physiological monitoring, drinking water management, meal identification, nutrition verification, meal supply and cloud reports can be realized, and the automation degree and data continuity of health management are improved.
Resumen de: CN122642894A
An analyte monitoring system comprising: a continuous analyte sensor configured to measure an analyte concentration of a host; a sensor electronics module configured to: receive a current from the continuous analyte sensor indicative of the analyte concentration; generating analyte data based on the current; transmitting the analyte data directly to a first display device using a wireless transmitter; and transmitting the analyte data directly to a second display device using the wireless transmitter; wherein the first display device comprises a smart watch; and the second display device comprises a smart phone.
Resumen de: NZ818091A
Some previously proposed diabetes treatment relies on sporadic readings (e.g., glucose readings) that do not provide ample data to effectively provide treatment options. Disclosed here is a system for providing glucose trend based behavior outputs for treatment of a glucose based condition,. The system comprising: a continuous glucose monitoring (CGM) device configured to output a plurality of glucose readings based on analyzing a bodily fluid over a period of time; a memory configured to store the plurality of glucose readings; and a processor configured to: determine a CGM trend based on a change in the plurality of glucose readings output by the CGM device and/or stored in the memory, wherein the CGM trend is determined using a CGM trace mapping the glucose readings over a period of time, and wherein the CGM trend is further based on at least one of a CGM event or a severity score; determine at least one behavior output based on the CGM trend and at least one additional factor, the at least one behavior output comprising insulin intake information; provide the at least one behavior output to a user; generate an optimized pathway to reach an ideal state based on one or more user vectors and the CGM trend, the ideal state corresponding to a good time in range (TIR) state and a good glucose variability (GV) state, the good TIR state being reached when a TIR value is greater than a TIR cutoff, the good GV state being reached when a GV value is greater than a GV cutoff, and the
Nº publicación: CN122642902A 28/08/2026
Solicitante:
MEDTRONIC MINIMED INC
\u7F8E\u6566\u529B\u8FF7\u4F60\u8FC8\u5FB7\u516C\u53F8
Resumen de: CN122642902A
Methods, systems, and devices for continuous glucose monitoring are disclosed. More specifically, the methods, systems, and devices describe a working electrode with a GOx sensor and a background electrode, where the background electrode does not have a GOx sensor. The system may then compare the first signal and the second signal to detect the user's ingestion of the medication. The system may generate a sensor blood glucose value based on the comparison.
BOPI
Sede Electrónica
